Table 2.
Sensitive analyses according to the presence or absence of PHAII Phenotype in the MANGUE cohort.
| |
No PHAII-like phenotype N=44 | PHAII-like phenotype N=14 | |
|---|---|---|---|
| Univariate analyses | p value | ||
| General characteristics | |||
| Age, years | 41.5 [34-56] | 56.5 [49-70] | 0.002 |
| Gender M/F, N (%) | 24/20 (54.5/45.5) | 11/3 (78.6/21.4) | 0.05 |
| BMI, kg/m² | 24 [21.9-28.8] | 24.9 [21.9-26.5] | 0.99 |
| First transplantation, N (%) |
36 (81.8) | 13 (92.9) | 0.43 |
| Living donors, N (%) | 5 (11.4) | 1 (7.1) | 1 |
| Delayed Graft function, N (%) |
3 (6.8) | 3 (21.4) | 0.14 |
| Expanded criteria donors, N (%) |
14 (32.6) | 8 (57.1) | 0.1 |
| Cardiovascular disease, N (%) |
6 (13.6) | 4 (28.6) | 0.23 |
| Hypertension before transplantation, N (%) |
32 (72.7) | 12 (85.7) | 0.48 |
| Diabetes (including NODAT), N (%) |
11 (25.0) | 3 (21.4) | 1 |
| Graft rejection before inclusion, N (%) |
2 (4.5) | 0 (0) | 1 |
| eGFR, ml/min/1,73m2 | 49 [34-67] | 33 [27-42] | 0.02 |
| Presence of proteinuria, N (%) |
9 (20.9) | 0 (0) | 0.09 |
| Treatment | |||
| Corticosteroids, N (%) | 27 (61.4) | 8 (57.1) | 0.78 |
| Mycophenolic acid, N (%) |
42 (95.5) | 11 (78.6) | 0.09 |
| TMP-SMX, N (%) | 38 (86.4) | 9 (64.2) | 0.06 |
| PPI use, N (%) | 17 (38.6) | 10 (71.4) | 0.03 |
| Nephropathy, N (%) | |||
| Glomerular | 12 (27.3) | 5 (35.7) | 0.31 |
| Tubulo-interstitial | 4 (9.1) | 2 (14.3) | |
| Vascular | 3 (6.8) | 0 (0) | |
| Diabetes | 3 (6.8) | 3 (21.4) | |
| Polycystic kidney disease |
5 (11.4) | 2 (14.3) | |
| Others (including unknown) |
17 (38.6) | 2 (14.3) | |
| Blood pressure | |||
| Hypertension, N (%) | 34 (77.3) | 14 (100) | 0.05 |
| SBP, mmHg | 134.5 [125-145] | 144.5 [134-156] | 0.03 |
| DBP, mmHg | 83 [75-89] | 83.5 [76-92] | 0.9 |
| Antihypertensive therapies | |||
| Number of antihypertensive agents |
1 [0.5-2] | 2 [2-3] | 0.002 |
| Calcium channel blocker, N (%) |
20 (45.5) | 7 (50.0) | 0.77 |
| Beta-blocker, N (%) | 9 (20.5) | 5 (33.7) | 0.24 |
| ACE inhibitors or ARB, N (%) |
11 (25) | 7 (11) | 0.08 |
| Diuretic except thiazides, N (%) |
3 (6.8) | 5 (35.7) | 0.006 |
| Others, N (%) | 7 (15.9) | 4 (28.6) | 0.43 |
| Acid base | |||
| Acidosis, N (%) | 29 (65.9) | 14 (100) | 0.01 |
| Blood [HCO3-], mM | 20 [18-21] | 21 [19-24] | 0.34 |
| Blood [HCO3-] < 22 mmol/L, N (%) |
10 (71,4) | 23 (52.3) | 0.21 |
| Alkaline supplementation, N (%) |
21 (47.7) | 8 (57.1) | 0.54 |
| Potassium | |||
| Hyperkalemia, N (%) | 8 (18.6) | 14 (100) | <0.0001 |
| [K+], mM | 4 [3.8-4.3] | 4.92 [4.7-5.2] | <0.0001 |
| [K+] >4.5 mmol/L, N (%) |
8 (18.6) | 14 (100) | <0.0001 |
| Potassium chelating agent use, N (%) |
0 (0.0) | 2 (14.3) | 0.06 |
| Multivariate analysis | Odds ratio [95% CI] | P value | |
| Age (1) | 1.9 [1.2-3.0] | 0.0058 | |
Quantitative data are presented as median [IQR]. Qualitative data were expressed as frequency (N) and percentages (%). All quantitative variables were tested using the Mann-Whitney test. For qualitative variables, the Chi-square test was used, except for the following variables, for which Fisher’s exact test was used: Nephropathy, first transplantation, hypertension before transplantation, Diabetes (including NODAT), Cardiovascular disease, Living donors, Delayed graft function, Mycophenolic acid, Graft rejection before inclusion, Antihypertensive therapies, potassium chelating agent use, beta-blocker, Calcium channel blocker, Beta-blocker, ACE inhibitors or ARB, diuretic except thiazides, TMP-SMX use, Acidosis. TMP-SMX, trimethoprim/sulfamethoxazole; PPI, proton pump inhibitor; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate. (1) Each ten-year increase.